东亚药业:2024年报净利润-1.01亿 同比下降183.47%

Financial Performance - The company reported a basic earnings per share of -0.90 yuan for 2024, a decrease of 184.11% compared to 1.07 yuan in 2023 [1] - The net profit for 2024 was -1.01 billion yuan, down 183.47% from 1.21 billion yuan in 2023 [1] - The operating revenue decreased by 11.65% to 11.98 billion yuan in 2024 from 13.56 billion yuan in 2023 [1] - The return on equity for 2024 was -5.19%, a decline of 182.38% from 6.30% in 2023 [1] - The net asset per share dropped to 0 yuan in 2024, a 100% decrease from 16.71 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 63.6984 million shares, accounting for 56.57% of the circulating shares, with a decrease of 2.7015 million shares compared to the previous period [1] - The largest shareholder, Chi Zhengming, holds 47.1168 million shares, representing 41.85% of the total share capital, with no change in holdings [2] - New entrants to the top ten shareholders include Zhang Decheng and Yang Haizhen, holding 0.6953 million shares and 0.6691 million shares respectively [2] - Two shareholders, Shen Ligang and Lu Yongkang, exited the top ten list [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [3]